nilotinib
Showing 26 - 50 of 110
Chronic Myelogenous Leukemia - Chronic Phase Trial in United States (Nilotinib)
Terminated
- Chronic Myelogenous Leukemia - Chronic Phase
- Nilotinib
-
Los Angeles, California
- +10 more
Jul 26, 2021
Leukemia Trial in Italy (drug, genetic, other)
Completed
- Leukemia
- imatinib mesylate
- +8 more
-
Rionero in Vulture, Potenza, Italy
- +36 more
Jan 3, 2022
Chronic Myeloid Leukemia Trial in Worldwide (nilotinib)
Active, not recruiting
- Chronic Myeloid Leukemia
- nilotinib
-
Los Angeles, California
- +61 more
Mar 17, 2022
CML, Chronic Myelogenous Leukemia, Leukemia, Myeloid Chronic Trial in Worldwide (Asciminib add-on, Imatinib, Nilotinib)
Recruiting
- CML
- +3 more
- Asciminib add-on
- +3 more
-
Augusta, Georgia
- +46 more
Jan 23, 2023
Chronic Myelogenous Leukemia Trial in Canada, United States (Nilotinib)
Completed
- Chronic Myelogenous Leukemia
- Nilotinib
-
Fayetteville, Arkansas
- +22 more
Jun 29, 2021
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia Trial in Aichi (Nilotinib)
Completed
- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Nilotinib
-
Aichi, JapanNovartis Investigative Site
Dec 6, 2020
Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)
Recruiting
- Chronic Myeloid Leukemia, Chronic Phase
- Withdrawal;Drug
- Imatinib withdrawal
- +2 more
-
Brno, Czechia
- +7 more
Aug 24, 2022
Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia Trial in Moscow
Active, not recruiting
- Chronic Myeloid Leukemia
- +2 more
- Imatinib
- +3 more
-
Moscow, Russian FederationNational Research Center for Hematology
Oct 1, 2020
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) Trial in Tokyo (Nilotinib)
Completed
- Chronic Myelogenous Leukemia
- Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
- Nilotinib
-
Tokyo, JapanNovartis Investigative Site
Dec 6, 2020
Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Worldwide (Nilotinib)
Completed
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Nilotinib
-
Bordeaux, Aquitaine, France
- +11 more
Dec 6, 2020
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia Trial
Completed
- Chronic Phase Chronic Myeloid Leukemia
- +4 more
- Nilotinib
- Ruxolitinib
-
Toronto, Ontario, CanadaPrincess Margaret Hospital / University Health Network
Oct 29, 2020
Soft Tissue Sarcoma Trial in France (drug, combination product, other)
Recruiting
- Soft Tissue Sarcoma
- Nilotinib
- +10 more
-
Bordeaux, France
- +17 more
Oct 4, 2022
Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia Trial in Worldwide (nilotinib)
Completed
- Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
- nilotinib
-
Loma Linda, California
- +35 more
Mar 25, 2021
Chronic Myelogenous Leukemia Trial in Turkey (Nilotinib)
Completed
- Chronic Myelogenous Leukemia
- Nilotinib
-
Eskisehir, Meselik, Turkey
- +12 more
Aug 18, 2020
Untreated Adult Acute Myeloid Leukemia Trial in Scottsdale, Rochester (Cytarabine, Daunorubicin Hydrochloride, Laboratory
Completed
- Untreated Adult Acute Myeloid Leukemia
- Cytarabine
- +4 more
-
Scottsdale, Arizona
- +1 more
Aug 4, 2020
(PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
Completed
- Gastrointestinal Stromal Tumors
- Nilotinib
-
Seoul, Korea, Republic ofAsan Medical Center
Jan 6, 2020
Bone Marrow Transplant Failure, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral Trial in Canada, United States (Nilotinib)
Completed
- Bone Marrow Transplant Failure
- +2 more
- Nilotinib
-
Stanford, California
- +4 more
Apr 13, 2020
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease Trial in United States (drug, other,
Recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Minimal Residual Disease
- Dasatinib
- +4 more
-
Goodyear, Arizona
- +237 more
Jan 3, 2023
Leukemia Trial in Houston (MEK-162, Nilotinib, Questionnaires)
Terminated
- Leukemia
- MEK-162
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Feb 10, 2020
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in United States (Bosutinib, Dasatinib, Laboratory Biomarker
Active, not recruiting
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Bosutinib
- +5 more
-
Anchorage, Alaska
- +540 more
Dec 14, 2022
Glioma Trial in La Jolla (nilotinib)
Completed
- Glioma
- nilotinib
-
La Jolla, CaliforniaThe Rebecca and John Moores UCSD Cancer Center
Apr 27, 2020
Philadelphia Positive (Ph+) Chronic Myeloid Leukemia Trial in Moscow (Nilotinib)
Terminated
- Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
- Nilotinib
-
Moscow, Russian FederationNovartis Investigative Site
Dec 9, 2019
Leukemia, Myelogenous, Chronic Trial in Houston (Nilotinib)
Completed
- Leukemia, Myelogenous, Chronic
- Nilotinib
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Sep 16, 2019
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Trial in Worldwide (Imatinib, Nilotinib, Bosutinib)
Recruiting
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
- Imatinib
- +4 more
-
Longmont, Colorado
- +128 more
Aug 1, 2022